Will Biomarkers Determine What Is Next in Multiple Sclerosis?

Stüve, Olaf; Racke, Michael K.

doi:10.1001/jamaneurol.2015.4841

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarkers other than the CXCL13 index have been utilized to attempt to predict future MS activity in ICDE and other forms of MS. One that has attracted the most excitement in the last few years, both for predicting inflammatory activity and correlating with axonal damage, has been serum neurofilament light, partly because of the easier accessibility of serum relative to CSF, discussed above, and reviewed recently ( 213 ). A detailed review of potential biomarkers is beyond the scope of this paper, but there have been several excellent reviews ( 214 , 215 ).…”

Section: Fiction #8 Long-term Outcomes Have Been Uniformly Improved I...mentioning

confidence: 99%

The Neuroimmunology of Multiple Sclerosis: Fictions and Facts

Pachner

2022

Front. Neurol.

View full text Add to dashboard Cite

There have been tremendous advances in the neuroimmunology of multiple sclerosis over the past five decades, which have led to improved diagnosis and therapy in the clinic. However, further advances must take into account an understanding of some of the complex issues in the field, particularly an appreciation of “facts” and “fiction.” Not surprisingly given the incredible complexity of both the nervous and immune systems, our understanding of the basic biology of the disease is very incomplete. This lack of understanding has led to many controversies in the field. This review identifies some of these controversies and facts/fictions with relation to the basic neuroimmunology of the disease (cells and molecules), and important clinical issues. Fortunately, the field is in a healthy transition from excessive reliance on animal models to a broader understanding of the disease in humans, which will likely lead to many improved treatments especially of the neurodegeneration in multiple sclerosis (MS).

show abstract

Section: Fiction #8 Long-term Outcomes Have Been Uniformly Improved I...mentioning

confidence: 99%

The Neuroimmunology of Multiple Sclerosis: Fictions and Facts

Pachner

2022

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Endophenotypes refer to subclasses present within one clinical diagnosis. 54 They have various manifestations that are linked to underlying genetic and epigenetic differences between individuals. 55 However, their divergence never exceeds the definitions of the background clinical syndrome.…”

Section: Endophenotypes In Ms Classificationmentioning

confidence: 99%

Clinical trials in multiple sclerosis: potential future trial designs

Manouchehri

Zhang

Salter

et al. 2019

Ther Adv Neurol Disord

Self Cite

View full text Add to dashboard Cite

Clinical trials of new treatments in multiple sclerosis (MS) currently require large sample sizes and long durations in order to yield reliable results. The differential responses of an already heterogeneous population of MS patients to individual disease-modifying therapies (DMTs) will further complicate future trials. MS trials with smaller samples and faster outcomes are conceivable through the substitution of current clinical and MRI outcomes with objectively measureable genomic and proteomic biomarkers. Currently, biomarkers that could be utilized for diagnosis and monitoring of MS disease activity are in the early validation phase. The power of single biomarkers or multiple correlated biomarkers to predict prognosis and response to treatment could initially be compared with currently accepted methods. These prospectively validated disease biomarkers could then be used to subcategorize the spectrum of MS patients into a finite number of endophenotypes with demonstrable different molecular pathogeneses and DMT response profiles. Newly developed DMT could potentially be assessed within specific endophenotypes and compared with pharmacogenomically relevant active comparator DMT. This approach may increase the efficiency of MS trials through homogenization of patient population and minimization of nonresponders in study groups, providing the potential for the development of targeted therapies.

show abstract

“…In the past 20 years RRMS has been transformed from a disease of relative hopelessness, with few, if any, treatment options to one of optimism and robust therapeutic promise (Ross & Thrower, 2010). The approval of immune modifying medications for RRMS is often cited as a major advance in our understanding, however many questions still remain unanswered (Stüve & Racke, 2016). Whilst the number of DMTs are rapidly increasing, there is still need to define which patients will respond to which drug and who is at higher risk of side effects (Stuve & Racke, 2016).…”

Section: Disease Modifying Treatments For Msmentioning

confidence: 99%

“…RRMS is also characterised by a complicated array of symptoms, which may affect sensory function, motor function, vision, gait, cognition, mood, bladder, bowel and sexual function amongst other many other signs and symptoms (Ben-Zacharia, 2011). There is currently no curative treatment for RRMS, although recently there have been major advances in more efficacious treatments called disease modifying therapies (DMTs) to minimise relapses and possibly prevent future disability (Stüve & Racke, 2016).…”

Section: Introductionmentioning

confidence: 99%

“Taming the Beast”: Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach

Burke

Vucic

Patching

2019

Res Theory Nurs Pract

View full text Add to dashboard Cite

Background and PurposeThe aim of this study was to gain insights and understanding into the lived experience of relapsing remitting multiple sclerosis (RRMS) in order to better inform patient-centerd nursing and healthcare.MethodsThis qualitative study used life history methodology, a form of focused ethnography, to explore the life history of 13 study participants living with RRMS. Semi-structured interviews were transcribed and analysed using thematic analysis.FindingsA total of eight key themes emerged, explaining the journey of living with RRMS. Commencing with “Piecing Together the Puzzle” of symptoms at the beginning of the RRMS journey, followed by “(Re)defining ME now that I have RRMS,” “Battling the Demons,” the experiences of “Surplus Suffering,” negotiating “High Invisibility,” gaining control by “Taming the Beast,” learning “The DMT Dance,” and ultimately “Holding Hands with Hope,” expressing hope and practising purposeful positivity.Implications for PracticeThe eight key themes of living with RRMS were reflective of the ebbs and flows of life. By gaining these insights into the world of people living with RRMS, it is anticipated that clinical nursing care and quality of life for people living with this chronic neurological disease may be improved.

show abstract

Will Biomarkers Determine What Is Next in Multiple Sclerosis?

Cited by 5 publications

References 8 publications

The Neuroimmunology of Multiple Sclerosis: Fictions and Facts

The Neuroimmunology of Multiple Sclerosis: Fictions and Facts

Clinical trials in multiple sclerosis: potential future trial designs

“Taming the Beast”: Exploring the Lived Experience of Relapsing Remitting Multiple Sclerosis Using a Life History Approach

Contact Info

Product

Resources

About